These companies haven't been fully recognized by the market, but are sure-fire revenue (and dividend) deliverers.
News & Analysis: Sanofi
The company says the deal will bolster its cancer immunotherapy efforts.
SNY earnings call for the period ending September 30, 2020.
As we (hopefully) approach the finish line in the COVID-19 vaccine race, it's a wonderful time to buy shares of Novavax and Sanofi.
The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.
There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.
These healthcare companies have had plenty of help in building the manufacturing capacity needed to produce billions of vaccine doses.
With competitors already in phase 3 development, the European drugmakers are just now starting a phase 1/2 clinical trial.
Sanofi and Regeneron reported a phase 3 failure with their rheumatoid arthritis treatment and severely affected COVID-19 patients.
These rough and tumble coronavirus stocks could help fund your retirement.